Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - COGENTIX MEDICAL INC /DE/ | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of the report (Date of earliest event reported): July 18, 2017
COGENTIX MEDICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
000-20970
|
13-3430173
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
5420 Feltl Road
|
||
|
Minnetonka, Minnesota
|
53343
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(952) 426-6140
Registrant's telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240. 14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition
|
On July 18, 2017, Cogentix Medical, Inc. (the “Company”) announced it had entered into an exclusive license with Promepla, a Monaco-based medical device manufacturer, to launch an Endo-Urology product line in the U.S.
A press release announcing this transaction has been attached as Exhibit 99.1 to this Current Report, and for context, the press release contains the revenue growth rate for the Company’s urology products during the second quarter ended June 30, 2017. The Company expects to issue a more complete earnings release for the second quarter ended June 30, 2017 in early August.
The Company is furnishing the information contained in this Current Report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits
|
| (d) |
Exhibits:
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated July 18, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
COGENTIX MEDICAL, INC.
|
|||
|
Date: July 18, 2017
|
By:
|
/s/ Brett Reynolds
|
|
|
Name:
|
Brett Reynolds
|
||
|
Title:
|
Senior Vice President and Chief Financial Officer
|
||
Exhibit Index
|
Exhibit Number
|
Description
|
|
|
Press Release, dated July 18, 2017
|